Predictive role of CYFRA 21-1 for S-1 monotherapy in non-small cell lung cancer patients

被引：9

作者：

Kagawa, Yusuke ^{[1
]}

Sone, Kazuki ^{[1
]}

Oguri, Tetsuya ^{[1
,2
,3
]}

Horiuchi, Minoru ^{[1
]}

Fukuda, Satoshi ^{[1
]}

Uemura, Takehiro ^{[1
]}

Takakuwa, Osamu ^{[1
]}

Maeno, Ken ^{[1
]}

Fukumitsu, Kennsuke ^{[1
]}

Kanemitsu, Yoshihiro ^{[1
]}

Tajiri, Tomoko ^{[1
]}

Ohkubo, Hirotsugu ^{[1
]}

Takemura, Masaya ^{[1
,2
]}

Ito, Yutaka ^{[1
]}

Niimi, Akio ^{[1
]}

机构：

[1] Dept Resp Med, Allergy & Clin Immunol, Nagoya, Japan

[2] Nagoya City Univ, Grad Sch Med Sci, Res Ctr Community Med, Dept Educ, Nagoya, Japan

[3] Nagoya City Univ, Grad Sch Med Sci, Res Ctr Community Med, Dept Educ, 1 Kawasumi,Mizuho Cho,Mizuho Ku, Nagoya, Aichi 4678601, Japan

来源：

RESPIRATORY INVESTIGATION | 2022年 / 60卷 / 03期

关键词：

Carcinoembryonic antigen; Cytokeratin; 19; fragment; Non-small cell lung cancer; S-1; Predictive marker; PHASE-III TRIAL; THYMIDYLATE SYNTHASE; CHEMOTHERAPY; DOCETAXEL; MARKER; COMBINATION; RESISTANCE; EFFICACY;

D O I：

10.1016/j.resinv.2021.11.014

中图分类号：

R56 [呼吸系及胸部疾病];

学科分类号：

摘要：

Background: S-1, an oral fluoropyrimidine derivative, is widely used for the treatment of several solid tumors. However, there are no predictive markers for its effectiveness.Methods: We retrospectively screened 108 patients with advanced non-small cell lung cancer (NSCLC) treated via S-1 monotherapy and investigated its relationship with cyto-keratin 19 fragment (CYFRA 21-1) and CEA pretreatment levels.Results: Sixty-one patients with high CYFRA 21-1 levels had a statistically significant shorter progression-free survival (PFS) and overall survival (OS) than 46 patients with normal levels (median PFS = 42 days vs. 70 days, respectively; p = 0.0014; median OS = 197 days vs. 316 days, respectively, p = 0.0239).Conclusions: Serum CYFRA 21-1 levels have predictive and prognostic roles in the man-agement of patients with advanced NSCLC on S-1 monotherapy.(c) 2022 Published by Elsevier B.V. on behalf of The Japanese Respiratory Society.

引用

页码：393 / 399

页数：7

共 31 条

[1] Safety and efficacy of nivolumab in combination with S-1/capecitabine plus oxaliplatin in patients with previously untreated, unresectable, advanced, or recurrent gastric/gastroesophageal junction cancer: interim results of a randomized, phase II trial (ATTRACTION-4) [J].

Boku, N. ;

Ryu, M. -H. ;

Kato, K. ;

Chung, H. C. ;

Minashi, K. ;

Lee, K. -W. ;

Cho, H. ;

Kang, W. K. ;

Komatsu, Y. ;

Tsuda, M. ;

Yamaguchi, K. ;

Hara, H. ;

Fumita, S. ;

Azuma, M. ;

Chen, L. -T. ;

Kang, Y. -K. .

ANNALS OF ONCOLOGY, 2019, 30 (02) :250-258

[2]

Dohmoto K, 2001, INT J CANCER, V91, P468

[3]

DOWECK I, 1995, ARCH OTOLARYNGOL, V121, P177

[4] Immunological Effects of Conventional Chemotherapy and Targeted Anticancer Agents [J].

Galluzzi, Lorenzo ;

Buque, Aitziber ;

Kepp, Oliver ;

Zitvogel, Laurence ;

Kroemer, Guido .

CANCER CELL, 2015, 28 (06) :690-714

[5] Pembrolizumab plus Chemotherapy in Metastatic Non-Small-Cell Lung Cancer [J].

Gandhi, L. ;

Rodriguez-Abreu, D. ;

Gadgeel, S. ;

Esteban, E. ;

Felip, E. ;

De Angelis, F. ;

Domine, M. ;

Clingan, P. ;

Hochmair, M. J. ;

Powell, S. F. ;

Cheng, S. Y. -S. ;

Bischoff, H. G. ;

Peled, N. ;

Grossi, F. ;

Jennens, R. R. ;

Reck, M. ;

Hui, R. ;

Garon, E. B. ;

Boyer, M. ;

Rubio-Viqueira, B. ;

Novello, S. ;

Kurata, T. ;

Gray, J. E. ;

Vida, J. ;

Wei, Z. ;

Yang, J. ;

Raftopoulos, H. ;

Pietanza, M. C. ;

Garassino, M. C. .

NEW ENGLAND JOURNAL OF MEDICINE, 2018, 378 (22) :2078-2092

[6] Impact of number versus location of metastases on survival in stage IV M1b non-small cell lung cancer [J].

Gibson, Amanda Jane Williams ;

Li, Haocheng ;

D'Silva, Adrijana ;

Tudor, Roxana A. ;

Elegbede, Anifat A. ;

Otsuka, Shannon Mary ;

Bebb, D. Gwyn ;

Cheung, Winson Y. .

MEDICAL ONCOLOGY, 2018, 35 (09)

[7] Postoperative CYFRA 21-1 and CEA as prognostic factors in patients with stage I pulmonary adenocarcinoma [J].

He, Ying ;

Cui, Yong ;

Chang, Dong ;

Wang, Tianyou .

ONCOTARGET, 2017, 8 (42) :73115-73122

[8] Carcinoembryonic antigen and cytokeratin-19 fragments for assessment of therapy response in non-small cell lung cancer: a systematic review and meta-analysis [J].

Holdenrieder, Stefan ;

Wehnl, Birgit ;

Hettwer, Karina ;

Simon, Kirsten ;

Uhlig, Steffen ;

Dayyani, Farshid .

BRITISH JOURNAL OF CANCER, 2017, 116 (08) :1037-1045

[9] Gefitinib Alone Versus Gefitinib Plus Chemotherapy for Non-Small-Cell Lung Cancer With Mutated Epidermal Growth Factor Receptor: NEJ009 Study [J].

Hosomi, Yukio ;

Morita, Satoshi ;

Sugawara, Shunichi ;

Kato, Terufumi ;

Fukuhara, Tatsuro ;

Gemma, Akihiko ;

Takahashi, Kazuhisa ;

Fujita, Yuka ;

Harada, Toshiyuki ;

Minato, Koichi ;

Takamura, Kei ;

Hagiwara, Koichi ;

Kobayashi, Kunihiko ;

Nukiwa, Toshihiro ;

Inoue, Akira ;

Kudoh, S. ;

Nagao, K. ;

Nakai, Y. ;

Yoshioka, T. ;

Harada, M. ;

Isobe, T. ;

Kasai, T. ;

Oizumi, S. ;

Kamimura, M. ;

Watanabe, S. ;

Okamoto, H. ;

Shingyoji, M. ;

Osaki, Y. ;

Hasegawa, Y. ;

Koyama, S. ;

Isobe, H. ;

Morikawa, N. ;

Ishida, T. ;

Ishii, Y. ;

Takiguchi, Y. ;

Watanabe, H. ;

Kurokawa, H. ;

Sunaga, N. ;

Mori, Y. ;

Tabata, T. ;

Nakagawa, T. ;

Kuyama, S. ;

Kiura, K. ;

Usui, K. ;

Soejima, K. ;

Nishitsuji, M. ;

Kinoshita, I ;

Taima, K. ;

Nishimura, N. ;

Kishi, K. .

JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (02) :115-+

[10] Propensity score-weighted analysis of chemotherapy after PD-1 inhibitors versus chemotherapy alone in patients with non-small cell lung cancer (WJOG10217L) [J].

Kato, Ryoji ;

Hayashi, Hidetoshi ;

Chiba, Yasutaka ;

Miyawaki, Eriko ;

Shimizu, Junichi ;

Ozaki, Tomohiro ;

Fujimoto, Daichi ;

Toyozawa, Ryo ;

Nakamura, Atsushi ;

Kozuki, Toshiyuki ;

Tanaka, Kentaro ;

Teraoka, Shunsuke ;

Usui, Kazuhiro ;

Nishino, Kazumi ;

Hataji, Osamu ;

Ota, Keiichi ;

Ebi, Noriyuki ;

Saeki, Sho ;

Akazawa, Yuki ;

Okuno, Motoyasu ;

Yamamoto, Nobuyuki ;

Nakagawa, Kazuhiko .

JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2020, 8 (01)

← 1 2 3 4 →